DIRS.INFO The most relevant business & tech news

The Dells contributed nearly $976 million to their charitable funds, which distribute gifts to a wide array of charities. Together, the 50 donors on the list contributed a total of $11.9 billion to charity in 2023. Only 23 of the richest Americans on the Forbes 400 list donated enough to appear on the Philanthropy rankings. 13 on the list, they contributed $210 million to the Institute for Protein Innovation, which shares its data with scientists for free. _____Maria Di Mento is a senior reporter and Jim Rendon is a senior writer at the Chronicle of Philanthropy, where you can read the full article.

Persons: Michael Bloomberg, Phil Knight, Penny, Michael Dell, Susan, Bill Gates, Melinda French Gates, Bernie Marcus, Ken Langone, Arthur Blank, “, ”, Renee Kaplan, — Franklin Antonio, Hugh Hoffman, —, Tim Springer, Chafen Lu, Diego’s Jay Kahn, Lauder, Sergey Brin’s, Michael J, Robert Kraft, Lucia Woods, David, Kathleen LaCross, Pierre Omidyar, Pam, They’re, John, Laura Arnold, Laura, ” Laura Arnold, Wendy Schmidt, Eric Schmidt, “ Younger, Kaplan, Jeff Sobrato, _____ Maria Di Mento, Jim Rendon, Kay Dervishi Organizations: New, New York City, Nike, Bloomberg, Knights, University of Oregon, Dells, Forbes, Forward, Qualcomm, Summer Science, SETI Institute, ALS Association , University of Cincinnati Foundation, Cincinnati Zoo, Botanical, Nature Center, Yale University, Institute for Protein Innovation, Price Club, Apple, San Diego Foundation, Discovery Foundation, Google, Fox Foundation, Parkinson’s Research, New England Patriots, Foundation, Combat, Ms, Foundation for Women, Chicago Foundation for Women, University of Virginia Darden School of Business, eBay, District of Columbia, Associated Press, Philanthropy Locations: New York, Portland , Oregon, Ohio, Moderna, California, Florida, Texas, Virginia, Washington, Hawaii, Massachusetts

☆ Cramer says get ready to buy if there's a market sell-off: 'I have my shopping list'
▼ + stars: | 2024-03-04 | by ( Julie Coleman | ) www.cnbc.com time to read: +2 min

CNBC's Jim Cramer on Monday disputed talk of sector bubbles, saying investors should be prepared to buy if there's a sell-off and undervalued stocks pull back. "I will be ready to buy if this market sells off," he said. He opined about the burgeoning artificial intelligence sector, saying that despite its current popularity, investors may not yet conceive of how influential this new technology will be. Cramer also pointed to Nvidia — which recently closed above the $2 trillion market cap — and said the company hasn't been overvalued. "I'm not fretting, I'm just expecting, and I have my shopping list of what to buy on weakness for the charitable trust."

Persons: CNBC's Jim Cramer, Cramer, hasn't, Wall, Nvidia's, —, Eli Lilly, I'm Organizations: Nvidia, Novo Nordisk

☆ Here are Monday's biggest analyst calls: Nvidia, Apple, Super Micro, Eli Lilly, Lyft, DoorDash, Disney & more
▼ + stars: | 2024-03-04 | by ( Michael Bloom | ) www.cnbc.com time to read: +9 min

UBS upgrades Norfolk Southern to buy from neutral UBS said it sees margin improvement for the railroad. Goldman Sachs initiates Super Micro as neutral Goldman said the stock is an "AI winner" but that valuation is full right now. UBS reiterates Eli Lilly as buy UBS raised its price target on the stock to $910 per share from $810. UBS reiterates Nvidia as buy UBS said it's sticking with its buy rating after a series of investor meetings with the company." Argus upgrades New York Times to buy from neutral Argus said it sees revenue growth for the newspaper company. "

Persons: Morgan Stanley, Disney, Piper Sandler, Piper, Guggenheim, Baird, SQSP, Goldman Sachs, Goldman, Bernstein, Tesla, underperform Bernstein, Eli Lilly, Wells, Melius, Citi downgrades Ferrari, Jefferies, Evercore, it's, Rosenblatt, Snowflake, Slootman's Organizations: BROS, Guggenheim, GSK, UBS, Norfolk Southern, Micro, JPMorgan, Nvidia, Kyverna Therapeutics, FLT, UDR, Conservative, America Health, RBC, Apple, Citi, Ferrari, Jefferies, BP, Barclays, Barclays downgrades, ISI, Toast Inc, Bank of America, Ball Corp, of America, Broadcom, New York Times Locations: Norfolk, China, New

☆ Jim Cramer says he really wants 'everyone to own' this nimble oil and energy stock
▼ + stars: | 2024-03-04 | by ( Morgan Chittum | ) www.cnbc.com time to read: +2 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Jim Cramer said the stock is a must-own tied to energy and oil. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER .

Persons: Jim Cramer, Dow, Eaton, Locker, Jerome Powell, Jim, Thomas Jorden, Eli Lilly, Lilly, Jim Cramer's Organizations: CNBC, Nasdaq, Nvidia, Broadcom, Costco, Capitol, Coterra Energy, Management, Wall, UBS, Club, Therapeutics Locations: AVGO, FL

What makes these stocks so formidable is the way they are "constantly reinventing themselves," Jeff Marks, the Club's director of portfolio analysis, said alongside Jim on stage. The Club portfolio, which consists of 32 stocks and cash, has nearly a 22% weighting in the Super Six. Let's consider how to allocate a hypothetical portfolio consisting of 12 stocks and 10% cash. Understanding how the stocks are linked creates an opportunity to build a well-rounded portfolio that balances risk and future returns. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

Persons: Jim Cramer, … I'm, Jim, Jeff Marks, Let's, Eli Lilly, Linde, –, Tim Cook, we're, it's, Jim Cramer's Organizations: Apple, Microsoft, Meta, Nvidia, Tesla, Palo Alto Networks, Costco, Linde, Google, Facebook, Amazon Web Services, Super, Jim Cramer's Charitable, CNBC Locations: Palo, Amazon, lockstep

☆ Viking Therapeutics emerges as a strong weight loss drug player — or takeover target
▼ + stars: | 2024-03-03 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +8 min

In this article VKTX Follow your favorite stocks CREATE FREE ACCOUNTCr | Istock | Getty ImagesBiotech company Viking Therapeutics has emerged as a strong potential entrant — or takeover target — in the budding weight loss drug market. Their treatments sparked the weight loss drug industry gold rush over the past year despite their hefty price tags and barriers to insurance coverage. It's too early to say whether Viking's drug could have an edge over existing or developing weight loss treatments. The pharmaceutical giant could also launch a slate of other weight loss treatments over the next few years that may have advantages over Zepbound, whether they offer more weight loss or convenience. That could give Viking the commercial and manufacturing capabilities needed to compete in the weight loss drug market.

Persons: Eli Lilly, Eli Lilly's Zepbound, Viking, Goldman Sachs, Eli Lilly’s, Brendan Mcdermid, GLP, Brian Lian, William Blair, Andy Hsieh, Hsieh, Eli Lilly's, Jefferies, Akash Tewari, doesn't, Mike Segar, Lian, William Blair's Hsieh, Oppenheimer, Jay Olson Organizations: Getty Images Biotech, Viking Therapeutics, Novo Nordisk, Reuters, Viking, Novo, U.S . Food, Drug Administration, Company, Deutsche Bank, CNBC Locations: New York City, Branchburg , New Jersey

☆ Here are Friday's biggest analyst calls: Nvidia, Apple, Dell, Netflix, Micron, Broadcom, Eli Lilly, New York Community Bancorp & more
▼ + stars: | 2024-03-01 | by ( Michael Bloom | ) www.cnbc.com time to read: +8 min

"We are initiating coverage of Evolent Health with an Outperform rating and $45 price target." Goldman Sachs downgrades Estee Lauder to neutral from buy Goldman downgraded the stock and said it's under "sizeable pressure." "We are upgrading Annexon (ANNX shares) to Overweight from Neutral and establishing a December 2024 price target of $11." Bank of America reiterates Eli Lilly as buy Bank of America raised its price target on the stock to $1000 per share from $800. "Following 4Q23 earnings we are upgrading GoodRx from Neutral to Overweight and increasing our December 2024 price target from $7 to $10."

Persons: Davidson, Campbell, Morgan Stanley, JD, TD Cowen, Parker, Dell, Goldman Sachs, Goldman, Louise Singlehurst, Tom Ford, Jefferies, Root, AVGO's, Stephens, Vita Coco, COCO, Piper downgrades, Piper, Redburn, Oppenheimer, Daiwa, Morgan Stanley downgrades Flywire, Goldman Sachs downgrades Estee Lauder, Estee Lauder, Dwight, Wells, Eli Lilly, Lilly, D.A Organizations: Apple, Vulcan, Merck, Vertex Pharmaceuticals, Bank of America, Broadcom, York Community Bancorp, Netflix, Micron, Mizuho, MU, Citi, EV, Health, Nvidia, Dwight, Hewlett Packard Enterprises, JPMorgan, biosciences, " Bank of America Locations: York, Davidson, Oshkosh, Minneapolis , MN

☆ Jim Cramer's Friday rapid fire: Dell, NYCB, Keurig Dr Pepper, Zscaler, Microsoft
▼ + stars: | 2024-03-01 | by ( Matthew J. Belvedere | ) www.cnbc.com time to read: +1 min

Jim Cramer's daily rapid fire looks at stocks in the news outside the CNBC Investing Club portfolio. "The material weakness was in the Federal Reserve to allow" failed Signature Bank to go to NYCB, Jim said. Zscaler : Shares of the cybersecurity stock were falling roughly 8%. Despite a beat and raise, Zscaler had a "billing issue not unlike the previous quarter at Palo Alto," Jim said. Cramer said private companies don't concern him but when they align with a public company like Club name Microsoft he pays attention.

Persons: Jim Cramer's, Jim Cramer, Jim, Keurig Dr Pepper, Eli Lilly, Zscaler, he's, Elon Musk, Sam Altman, Cramer Organizations: CNBC, Club, Dell, New York Community Bancorp, Federal Reserve, Bank, Palo Alto Networks, Microsoft, Elon Locations: Palo

☆ An analyst call on red-hot Broadcom indicates a possible buying opportunity ahead
▼ + stars: | 2024-03-01 | by ( Morgan Chittum | ) www.cnbc.com time to read: +2 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Oppenheimer, BofA, Jim, Eli Lilly's, Lilly, Jim Cramer's Organizations: CNBC, Nasdaq, Dow, Wall Street, Broadcom, Bank of America, Club, FDA

☆ CNBC Daily Open: Markets brace for Fed's key inflation gauge
▼ + stars: | 2024-02-29 | by ( Sumathi Bala | ) www.cnbc.com time to read: +2 min

A trader works during the closing bell at the New York Stock Exchange (NYSE) on March 17, 2020 at Wall Street in New York City. This report is from today's CNBC Daily Open, our international markets newsletter. CNBC Daily Open brings investors up to speed on everything they need to know, no matter where they are. Overnight, Wall Street ended lower as the 30-stock Dow slipped 0.06% and fell for a third consecutive session. Water scarcity threatens chip makersWater shortages could threaten semiconductor firms such as Taiwan Semiconductor Manufacturing Company, S&P Global Ratings said in a report.

Persons: Dow, Sundar Pichai, Pichai, Ziyu Shen, Eli Lilly, Freddie Lait, Lait Organizations: New York Stock Exchange, Wall, CNBC, CSI, Nikkei, Nasdaq, Google, Taiwan Semiconductor Manufacturing, Nvidia Geely, Nvidia, Novo Nordisk, McKesson Locations: New York City, Asia, U.S

☆ Here is Eli Lilly's competitive edge in GLP-1 obesity drugs and Abbott's secondary play
▼ + stars: | 2024-02-29 | by ( Jeff Marks | ) www.cnbc.com time to read: +4 min

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street.

Persons: Jim Cramer, Dow, Jim, Chris Danely, Cramer, Eaton, Eli Lilly, Lilly, Jim Cramer's Organizations: CNBC, Dow, Nasdaq, Semiconductor, Citi, Broadcom, Nvidia, Devices, Micron, Dell Technologies, Autodesk, Novo Nordisk, Abbott Laboratories, Novo, Viking, Jim Cramer's Charitable

☆ 'Exciting idea': Fund manager loves this pharma stock — and analysts see more upside ahead
▼ + stars: | 2024-02-29 | by ( Amala Balakrishner | In Amala-Balakrishner | ) www.cnbc.com time to read: +3 min

But one firm in the wider ecosystem that's perhaps lesser known stands out to fund manager Freddie Lait, which is McKesson Corp — the U.S. pharmaceuticals distribution company. Calling the company an "exciting idea," Lait noted that the 100-year-old business is "very defensive and very diversified." Lait manages over $750 million collectively between two funds — the Latitude Horizon Fund and the Latitude Global Fund . Of the 19 analysts covering the stock, 14 give it a buy or overweight rating, while three have hold ratings and one has a sell rating. The average price target on the stock is $550.25, according to FactSet data, giving it potential upside of 6%.

Persons: Eli Lilly, Freddie Lait, Lait, —, That's, … It's, McKesson, MCK, — CNBC's Michael Bloom Organizations: Novo Nordisk, Latitude Investment Management, CNBC, U.S, Cardinal Health, McKesson Corp, JPMorgan, Rite Aid, receivables, Leerink Partners, pharma

☆ S&P on pace to score fourth month of consecutive gains. History tells us what could come next
▼ + stars: | 2024-02-29 | by ( Bob Pisani | ) www.cnbc.com time to read: +3 min

The S & P 500 is ending February with a gain of almost 5%. S & P 500: Four big months November: up 8.9% December: up 4.4% January: up 1.6% February: up 4.6% The November gain of 8.9% was one of the 20 best monthly performances in history. The S & P has advanced about 5% since passing the old January 2022 historic high, which it crossed on Jan. 19, this year. Put another way: the S & P has recovered all the bear market losses from the old high in January 2022 to the bear market bottom in October 2022, and added another 5%. "Yet it also offers encouragement that no post-recovery selloff saw the start of a new bear market before rebounding and proceeding onto additional new highs."

Persons: Steve Starker, Todd Sohn, Eli Lilly, Nicholas Colas, Sam Stovall Organizations: Nvidia, P, Technology, Services, Care, Broadcom, Communication Services, Meta, Health Care, Merck, Depot, Costco, JPMorgan, Mastercard, Berkshire Hathaway, Research Locations: BTIG

☆ Eli Lilly and Novo Nordisk will remain leaders in the weight-loss drug market: Mizuho's Jared Holz
▼ + stars: | 2024-02-29 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEli Lilly and Novo Nordisk will remain leaders in the weight-loss drug market: Mizuho's Jared HolzCNBC’s Melissa Lee and Jared Holz, Mizuho Securities America healthcare sector strategist, join 'Squawk on Street' to discuss the weight-loss drug market, why he believes Eli Lilly and Novo Nordisk will remain the frontrunners for the next 2-3 years, and more.

Persons: Eli Lilly, Jared Holz, Melissa Lee Organizations: Novo Nordisk, Mizuho Securities Locations: Mizuho Securities America

☆ CNBC Daily Open: Wall Street on edge over Fed's key inflation gauge
▼ + stars: | 2024-02-29 | by ( Sumathi Bala | ) www.cnbc.com time to read: +2 min

This report is from today's CNBC Daily Open, our international markets newsletter. CNBC Daily Open brings investors up to speed on everything they need to know, no matter where they are. Markets declineWall Street ended lower Wednesday as investors anxiously wait for the personal consumer expenditures reading for January due today. [PRO] A lesser-known pharma standoutInvestors have been piling into major weight-loss drug manufacturers like Eli Lilly and Novo Nordisk. But fund manager Freddie Lait picked a lesser-known firm that also stands out: McKesson Corp — the U.S. pharmaceuticals distribution company.

Persons: Jerome Powell, Dow, Sundar Pichai, Pichai, Tim Cook, Cook, Walt Disney, Mukesh Ambani, Eli Lilly, Freddie Lait, Lait Organizations: Federal Reserve, New York Stock Exchange, CNBC, Nasdaq, Google, Apple, Walt, Reliance, Asia's, JV, Novo Nordisk, McKesson Locations: New York City, U.S, India

☆ Jim Cramer says stay clear of this retail stock: 'It is not something you want to own'
▼ + stars: | 2024-02-28 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +2 min

First Solar : Shares rose more than 3% after the solar firm's quarterly earnings topped estimates, and its guidance was formidable. Urban Outfitters : Shares fell 13% after earnings, revenue and same-store sales growth missed Wall Street's expectations. While Cramer complimented the performance of its clothing-rental business, Nuuly, he said investors should not view Urban Outfitters as much more than an industry temperature check. That seems like good news for GE Healthcare , according to Cramer, whose Charitable Trust also owns shares of the medical-equipment maker. GE Healthcare has been the best-performing health-care stock in the S & P 500 in February, "and it's not done," Cramer said.

Persons: Jim Cramer's, Cramer, Eli Lilly Organizations: CNBC, Club, Novo Nordisk, Charitable Trust, Universal Health Services, GE Healthcare, Trust

☆ Watch out: These stocks are too expensive as the market trades near record highs
▼ + stars: | 2024-02-28 | by ( Sarah Min | ) www.cnbc.com time to read: +1 min

It could be time to take some profits with stocks near record highs. But that same hot streak is making some stocks look expensive. Wall Street's biggest artificial intelligence darling surfaced on the screen for most expensive stocks. But the company's trailing 12-month P/E ratio (P/E TTM) of 65.5 suggests the stock is overvalued, especially when compared to its historical earnings. But Eli Lilly's P/E ratio on a trailing 12-month basis of 130.5 shows the stock is expensive.

Persons: Eli Lilly, Eli Lilly's Organizations: Dow Jones, CNBC, Stock, Nvidia, Merck

☆ The pet drugs vets are now prescribing look a lot more like human medications
▼ + stars: | 2024-02-28 | by ( Ian Thomas | ) www.cnbc.com time to read: +7 min

If you want to understand how different the human and animal medicine and vaccine industries have historically been, you don't need to look much further than weight loss drugs. When Pfizer spun off its animal health business in 2013 creating Zoetis, about 65% of the company's business was livestock-related. That has flipped now, with 64% of the company's revenue coming from products for companion animals like cats and dogs. Peck credits the Pfizer spinoff for allowing Zoetis to better balance what the company wanted to do in animal health versus the human health side. A similar product was approved for cats, marking the first time that monoclonal antibody treatments, which have become increasingly popular for treating human illnesses, have been used to treat pet osteoarthritis pain.

Persons: Kristin Peck, Eli Lilly, Peck, Zoetis, We've, it's, We'll Organizations: CNBC, Novo Nordisk, Pfizer, AstraZeneca, FDA

☆ Thinking about taking new weight loss drugs? These are the big health risk decisions that will follow
▼ + stars: | 2024-02-28 | by ( Eric Rosenbaum | ) www.cnbc.com time to read: +6 min

In this article NOVO.B-DKLLYWWGWW Follow your favorite stocks CREATE FREE ACCOUNTAn injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. But will Americans trust the most iconic brand in the legacy weight-loss business to guide them into its future? "Big pharma was coming for weight loss, and if they didn't have a clinical angle, they would have run the risk of becoming an irrelevant company." "This is a new, incredibly powerful and effective class of pharmaceuticals that a lot of people will find help improve their health." watch nowRisks of overreliance on obesity drugs The risk is real that providers may use the medications and "forget about lifestyle," said John Batsis, an associate professor and nutrition expert at the University of North Carolina Chapel Hill's school of public health.

Persons: Eli Lilly’s, Brendan Mcdermid, Eli Lilly, —, Sima Sistani —, Sistani, Alex Fuhrman, Hallum, Fuhrman, Davidson, Linda Bolton Weiser, I've, Geoff Cook, Cook, John Batsis, Batsis Organizations: Reuters, Novo Nordisk, CNBC, Craig, pharma, University of North, University of North Carolina Chapel Locations: New York City, U.S, Herbalife, University of North Carolina

☆ Cramer gives the portfolio's core holdings a makeover — 4 are booted, 6 are added including a trio of tech giants
▼ + stars: | 2024-02-28 | by ( Morgan Chittum | ) www.cnbc.com time to read: +12 min

COST 5Y mountain Costco's stock performance over the past five years. DHR 5Y mountain Danaher's stock performance over the past five years. ETN 5Y mountain Eaton Corp.'s stock performance over the past five years. "The megatrends are real serious, and [Eaton] is a real serious company," Jim said. TJX 5Y mountain TJX Companies' stock performance over the past five years.

Persons: Jim Cramer, Jeff Marks, Morgan Stanley, Wall, Beijing's, Jim, Eaton, Linde, Lilly's, Eli Lilly, We've, Zepbound, Mark Zuckerberg's, Mark Zuckerberg, OpenAI, Copilot, management's, Nvidia, TJ Maxx, TikTok, Gen Zers, TJX, Jim Cramer's, Satya Narayana Nadella, Lucas Jackson Organizations: GE Healthcare, Meta, Microsoft, Johnson, Natural Resources, Starbucks, Apple, Apple Music, Services, Amazon, Amazon Web Services, Prime, Costco, Danaher, Eaton Corp, Investors, GE, LIN, Novo Nordisk's Wegovy, Novo Nordisk, Management, Nvidia, TJX Companies, Marshalls, CNBC Locations: Eaton, China, Manhattan, New York City

☆ Viking Therapeutics' weight loss drug showed faster results in clinical trials than Ozempic or Wegovy. Here's how it works.
▼ + stars: | 2024-02-28 | by ( ) www.businessinsider.com time to read: +3 min

Biotech company Viking Therapeutics saw stock prices double after a report on weight loss drug VK2735. The new drug could lead to even more weight loss at a faster pace than Ozempic or Mounjaro. Viking Therapeutics, a small California-based biotech company, shared the topline results from a mid-stage trial of its drug VK2735 on February 27. AdvertisementHowever, the early results of clinical trials suggest it could be on par to offer even more weight loss in less time than its competitors. How Viking Therapeutics' weight-loss drug worksVK2735 mimics two hormones that affect weight control.

Persons: —, Eli Lilly, GIP, VK2735 Organizations: Biotech, Viking Therapeutics, Service, Novo Nordisk, Washington Post, Therapeutics, Viking Locations: California

☆ One down one to go — what we learned from TJX's great quarter and hope to hear from Salesforce
▼ + stars: | 2024-02-28 | by ( Morgan Chittum | ) www.cnbc.com time to read: +2 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Eli Lilly shares fell 1% on Wednesday following a similar drop in the prior session. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Salesforce, Jim, Let's, Eli Lilly, Jim Cramer's Organizations: CNBC, TJX Companies, Management, Therapeutics Locations: GLP

☆ CNBC Changemakers: Fortune 500 CEOs, Naomi Osaka and Alex Cooper share a success secret
▼ + stars: | 2024-02-28 | by ( Julia Boorstin | ) www.cnbc.com time to read: +5 min

Leading the way are health care, with 22%; tech, with 14%; and consumer products and financial services, tied at 10%. Kate Ryder is closing major gaps in women's and family health care with Maven. Michelle Zatlyn, co-founder and chief operating officer at Cloudflare, is giving companies AI tools to bolster cybersecurity and lower costs for vulnerable, critical infrastructure providers, including schools and local election systems. The Changemakers serve as a reminder that success is a result of leading in ways that are authentic. In the book she explored the concept of "reformers" — women working to fix broken systems.

Persons: Anat Ashkenazi, Eli Lilly, Svanika Balasubramanian, Bobbie, Laura Modi, Baby2Baby, Norah Weinstein, Kelly Sawyer Patricof, Alex Cooper, Tracee Ellis Ross, Naomi Osaka, Balasubramanian, Jessica Chang, Maayan Cohen, Kate Ryder, Maven, Monique Rodriguez, Jessica Berman, Kathy Hannun, Clara Shih, Michelle Zatlyn, Kristin Peck, Julia Boorstin Organizations: CNBC, U.S, RePurpose Global, rePurpose, Women's Soccer League, Dandelion Energy, cybersecurity Locations: Changemakers, Cloudflare

Berenberg increased its price target on Eli Lilly on the back of expected strong sales of its weight loss drug, Zepbound. The firm kept its $21 price target, saying shares are "ready to inflect" with hardware cost deflation and investment tax credit boosting growth. Danely's $820 price target on the buy-rated blockbuster chipmaker suggests 3.6% potential upside for shares since Monday's close. — Pia Singh 5:38 a.m.: Berenberg hikes Eli Lilly price target Eli Lilly has been on a tear this year, and Berenberg expects even more gains from here. Analyst Kerry Holford reiterated his buy rating on the stock and raised his price target to $850 from $680.

Persons: Berenberg, Eli Lilly, John Hodulik, Hodulik, — Pia Singh, Wells, Steven Cahall, Cahall, ROKU, Fred Imbert, BofA Evercore, James West, Christopher Danely, Danely, Goldman Sachs, Edward Jones, James Shanahan, Goldman, Marcus, Apiro Dounls, Sunoco, Kerry Holford, Holford, Zepbound Organizations: CNBC, pharma, Nvidia, Citi, Sunoco, NuStar Energy, Netflix, UBS, Vizio, CTV, ISI, BofA, BofA Evercore ISI, Bank of America, Micron Technology, NuStar, SUN Locations: Wells, Sunrun, Monday's

☆ Cramer says the price target bump for this stock ahead of its earnings is a 'red flag'
▼ + stars: | 2024-02-27 | by ( Morgan Chittum | ) www.cnbc.com time to read: +2 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. But Jim Cramer said the biggest theme in the market right now is cybersecurity. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER .

Persons: Jim Cramer, Jim, Eli Lilly, Jim assuaged, it's, Wells Fargo, Jim Cramer's Organizations: CNBC, Palo Alto Networks, Viking Therapeutics

Search resuls for: "Eli Lilly

25 mentions found